pharmacokinetics and pharmacodynamics of multiple 5 mg doses of bi 1356 p.o. given once daily compared to multiple 2.5 mg doses given twice daily in healthy male and female volunteers

Conditions: Healthy

Summary: the objective was to investigate the influence of 2 different dosage regimens (5 mg once daily vs. 2.5 mg twice daily) on the steady-state pharmacokinetics and pharmacodynamics of orally administered bi 1356.


Eligibility criteria:
inclusion criteria: * healthy females and males based upon a complete medical history, including the physical examination, vital signs (bp, pr), 12-lead ecg, clinical laboratory tests * age ≥18 and age ≤65 years * bmi ≥18.5 and bmi ≤29.9 kg/m² (body mass index) * signed and dated written informed consent prior to admission to the study in accordance with good clinical practice and the local legislation exclusion criteria: * any finding of the medical examination (including bp, pr and ecg) deviating from normal and of clinical relevance * any evidence of a clinically relevant concomitant disease * gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders * surgery of the gastrointestinal tract (except appendectomy) * diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders * history of relevant orthostatic hypotension, fainting spells or blackouts * chronic or relevant acute infections (e.g. hiv) * history of relevant allergy/hypersensitivity (including allergy to drug or its excipients) * intake of drugs with a long half-life (\> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial * use of drugs which might reasonably influence the results of the trial or that prolong the qt/qtc interval based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial * participation in another trial with an investigational drug within two months prior to administration or during the trial * smoker (\> 10 cigarettes or \> 3 cigars or \> 3 pipes/day) * inability to refrain from smoking on trial days * alcohol abuse (more than 60 g/day) * drug abuse * blood donation (more than 100 ml within four weeks prior to administration or during the trial) * excessive physical activities (within one week prior to administration or during the trial) * any laboratory value outside the reference range that is of clinical relevance * inability to comply with dietary regimen of trial site * a marked baseline prolongation of qt/qtc interval (e.g., repeated demonstration of a qtc interval \>450 ms) * a history of additional risk factors for torsade de pointes (tdp) (e.g., heart failure, hypokalemia, family history of long qt syndrome) for male subjects: * not willing to use adequate contraception (condome use plus another form of contraception e.g. spermicide, oral contraceptive taken by female partner, sterilisation, iud (intrauterine device)) during the whole study period from the time of the first intake of study drug until one month after the last intake for female subjects: * pregnancy or planning to become pregnant within 2 months of study completion * positive pregnancy test * are not willing or are unable to use a reliable method of contraception (such as implants, injectibles and combined oral contraceptives, sterilisation, iud, double barrier method) for at least 3 months prior to participation in the trial, during and up to 2 months after completion/termination of the trial * chronic use of oral contraception or hormone replacement containing ethinyl estradiol as the only method of contraception * lactation period